Clinical Trials Logo

Clinical Trial Summary

Energy healing is among the most commonly used forms of complementary and alternative medicine among cancer patients. There are, however, few studies on the effects of energy healing for cancer and cancer associated symptoms and none of them are of a volume or quality that allows reliable conclusions to be drawn. Qualitative studies on energy healing in Denmark have demonstrated that the interventions are individualized and the expected outcomes personalized. This research points to the need for a research design that can evaluate personalized outcomes of individualized treatments and at the same time adhere to general demands of external and internal validity.

The objective of this study is to test the effectiveness of energy healing as an individualized rehabilitative intervention to improve outcomes of personal choice among persons who have completed a conventional intended curative treatment for colorectal, breast and prostate cancer. The study is designed as a pragmatic clinical trial with personalized outcomes.

The study attempts to maximize external validity by using a design that incorporates important features of energy healing administered in real-life settings: 1a) allowing participants self-selection to healing and non-healing control, 1b) assessing individual participant-selected treatment goals, 1c) allowing the treatment to be performed in the private clinics of the healers. To maximize internal validity similar to that obtained in a randomized, clinical trial design, the study will 2a) randomize participants to self-selection and randomized groups of intervention and control; and 2b) supplement the assessment of personalized treatment goals with assessment of outcomes with standardized measures.

The study will account for a number of possible moderators of the effects, including 3a) socio-demographics and 3b) previous experience with complementary and alternative treatment. Outcome measures will be assessed by questionnaires, physical measurements, data from administrative registries as well as semi-structured interviews and participant observation. Possible patterns in the various forms of data will be examined for concordances and discrepancies.

Finally, the methods will be discussed in terms of their generalizability as a model for evaluating personal outcomes of individualized treatments with high levels of external and internal validity.


Clinical Trial Description

PRIMARY OUTCOMES AND HYPOTHESES

The primary outcome is to investigate whether "energy healing" as an individualized form of treatment can improve personal concerns identified by the individual patient in the MYCaW questionnaire.

Hypotheses:

- The effects found will be larger for the primary, personalized, outcomes (MYCaW) than when assessed with standardized measures.

- Patients that self-select energy healing will experience larger effects for primary outcomes than patients that randomized to the intervention.

- The primary, personalized outcomes will change more during the course of the treatment in the intervention groups than in the control groups.

SECONDARY OUTCOMES AND HYPOTHESES

Secondary outcomes concern three independent but related areas: (1) Will energy healing have a statistically significant (p < 0.05) effect on secondary outcomes assessed with standardized, validated instruments, including physical health survey, physical activity, cancer-related QoL, depressive symptoms, and mood? (2) Will energy healing have a positive impact on daily physical performance as subjectively described in dairies? (3) Will energy healing influence participants' subjective experience of their illness and recovery? (4) Will energy healing influence participants' self-reported burden of late effect after cancer treatment?

Hypotheses:

- No significant effects of healing on secondary, standardized, outcomes (Physical health survey, physical activity, QoL, Depressive symptoms, mood) are anticipated.

- No significant effect on levels of daily physical performance as reported in diaries is anticipated.

- Participants that self-select energy healing will report significantly larger effects on secondary outcomes than patients randomized to intervention.

- No significant effect on participants' self-reported burden of late effects is anticipated.

Further, it is expected that the qualitative analysis will inform whether the energy healing provides participants with images that are embodied in their perception of self, illness and recovery and whether this is acknowledged by participants as meaningful for them in the particular situation in which they are embedded.

HYPOTEHSES RELATED TO MEDIATION AND MODERATION OF EFFECTS

A number of factors are anticipated to mediate and moderate the effects of energy healing.

Hypotheses:

- The effect of healing will be larger, if participants o report higher levels of "absorption" (i.e. "openness to experience")

- report higher expectations of benefits

- report previous positive experience with CAM

- report a positive attitude towards CAM

- report prior experience with energy healing

- report faith in God or a higher spiritual power

- experience a better healer-patient relationship

- Those that change their primary selected outcome over the course of treatment will score higher on the questionnaire relating to the healer-patient relationship.

Further, it is expected that the qualitative analysis will shed light on whether and how

- participants subjectively express a change in their perception of self and illness corresponding with the healer's recommendations;

- ritualization of the healing session provides for participants' subjective acknowledgement of the healer-patient relationship;

The quantitative and qualitative data in combination are expected to confirm the following hypothesis:

- If the healer is able to ritualize, orchestrate and 'key' the performance of the healing ritual by means of stylistic devices as e.g. the burning of incense, music, etc., and if he/she is a skilled symbol manager, and if the participant subjectively acknowledge these aspects, the participant will score high on standardized questionnaires.

TERTIARY OUTCOMES

Finally, a number of issues will be explored relating to the value attributed to the treatment by the participants. It will be explored:

- How much money are the participants in the intervention groups willing to spend on this kind of therapy

- How far a distance participants are willing to drive to receive this kind of therapy

STUDY DESIGN

The study is a pragmatic trial allowing healers to adjust the intervention (energy healing) to each participant and to undertake treatment-related communication as usual. The study is designed to allow for analysis of the implications of self-selection by randomizing participants to a self-selection arm and a randomized arm, each arm with corresponding control groups. Finally, the study design allows participants to identify what they consider to be their primary outcomes by using open outcome forms and semi-structured interviews in conjunction with validated, standard measures. In order to encompass the expected variation in primary outcomes and to investigate the interrelations of different types of outcomes, the study is designed as a cross-disciplinary investigation.

RECRUITMENT

125 persons for the treatment groups and 200 persons for the control groups will be recruited in two ways; 1) Lists of patients who have completed their hospital treatment for colorectal, breast and prostate cancer within the last 12 months will be extracted from The National Patient Registry, and, 2) lists of patients who have completed intended curative treatment for colorectal cancer within the last month will be provided by the involved hospital departments from the Region of Southern Denmark. All patients considered eligible are randomized to self-selection arm (SSA) or randomization arm (RA) and mailed: 1) A letter inviting them to participate in the study, 2) Information about the study and the group they are assigned to, 3) A baseline questionnaire, 4) An informed consent form, allowing them to be contacted by the research team and a healer, and 5) A pre-paid return envelope. All invited persons are then contacted by telephone in order to answer any questions they may have concerning the study. Persons willing to participate are asked to complete the baseline questionnaire and the informed consent form and return these. Persons who are unwilling to participate will be asked for the reasons and a drop-out register will be established. After two consecutive reminder calls and no response, a participant will be considered a drop-out (see Figure 1).

After allocation of participants to healers, the healers are contacted by telephone and letter with information on the participants and repetition of the procedure to be followed. The healers will arrange contacts to the participants who have been assigned to receive energy healing within two days in order to agree on a date for the first session.

All project procedures will be administered and organized using an encrypted ACCESS database aligned with the study protocol procedures. Day-to-day data collection activities will thus be based on computerized enquiries, and all procedural and unplanned events, such as i.e. patient telephone calls, will be registered.

RANDOMIZATION

Possible participants are initially and before the first contacts randomized to SSA and RA by a centralized, computerized procedure, e.g. the Minim (Minimisation Program for Allocating Patients to Treatments in Clinical Trials). Stratified; The sample will be stratified according to type of cancer and gender.

Following the reception of baseline questionnaires and informed consent form from the group randomized to the RA, the RA is further randomized to intervention and control groups by a similar procedure.

ASSESSMENT

Questionnaires:

Baseline questionnaires will be administrated before first treatment. Additional questionnaire packages will be administered to the participants 10 days, 10 weeks and 18 weeks after baseline. Additionally, those in the healing intervention groups complete questionnaire packages immediately before and after their third healing session. For comparison the control groups complete a questionnaire package 6 weeks after baseline.

Diaries:

20 participants from each of the four groups are asked to fill in an activity diary (conc. activities from sleep to strenuous activity) and time consumption (minutes and hours) during the day. The activity diary will be completed for seven days at baseline, seven days at week 10 and seven days at week 18.

Qualitative semi-structured interviews:

8 participants from each of the two intervention groups and control groups will be included for qualitative interviews and participant observation. The interviews and participant-observation will be conducted before and after the treatments and enable comparison of dispositions and processes of change. Interviewees will be selected to ascertain distribution in age and previous use of CAM (particularly energy healing). All interviews will be recorded if the participants are comfortable with it.

Participant-observation:

12 participants will be followed with 1 day's participant-observation before the first treatment and 2 days' participant-observation after the final treatment in settings, which the patient consider as important domains in his/her life and in the 'returning-to-life' process. Further, participant-observation will be conducted in some of the clinics involved in the trial. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT01434264
Study type Interventional
Source University of Southern Denmark
Contact
Status Completed
Phase N/A
Start date September 2011
Completion date November 2012

See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A